Your browser doesn't support javascript.
loading
LILRB2 interaction with HLA class I correlates with control of HIV-1 infection.
Bashirova, Arman A; Martin-Gayo, Enrique; Jones, Des C; Qi, Ying; Apps, Richard; Gao, Xiaojiang; Burke, Patrick S; Taylor, Craig J; Rogich, Jerome; Wolinsky, Steven; Bream, Jay H; Duggal, Priya; Hussain, Shehnaz; Martinson, Jeremy; Weintrob, Amy; Kirk, Gregory D; Fellay, Jacques; Buchbinder, Susan P; Goedert, James J; Deeks, Steven G; Pereyra, Florencia; Trowsdale, John; Lichterfeld, Mathias; Telenti, Amalio; Walker, Bruce D; Allen, Rachel L; Carrington, Mary; Yu, Xu G.
Afiliação
  • Bashirova AA; Cancer and Inflammation Program, Laboratory of Experimental Immunology, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America; Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, United States of America.
  • Martin-Gayo E; Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, United States of America.
  • Jones DC; Department of Pathology, Cambridge University, Cambridge, United Kingdom.
  • Qi Y; Cancer and Inflammation Program, Laboratory of Experimental Immunology, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
  • Apps R; Cancer and Inflammation Program, Laboratory of Experimental Immunology, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
  • Gao X; Cancer and Inflammation Program, Laboratory of Experimental Immunology, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
  • Burke PS; Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, United States of America.
  • Taylor CJ; Tissue Typing Laboratories, Addenbrookes Hospital, Cambridge, United Kingdom.
  • Rogich J; Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, United States of America.
  • Wolinsky S; Northwestern University Medical School, Chicago, Illinois, United States of America.
  • Bream JH; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
  • Duggal P; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
  • Hussain S; Fielding School of Public Health, University of California at Los Angeles, Los Angeles, California, United States of America.
  • Martinson J; University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
  • Weintrob A; USU Infectious Disease Clinical Research Program, Bethesda, Maryland, United States of America.
  • Kirk GD; Johns Hopkins University School of Public Health, Baltimore, Maryland, United States of America.
  • Fellay J; School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
  • Buchbinder SP; San Francisco Department of Public Health, San Francisco, California, United States of America.
  • Goedert JJ; Division of Cancer Epidemiology & Genetics, NCI, Bethesda, Maryland, United States of America.
  • Deeks SG; University of California at San Francisco Medical School, San Francisco, California, United States of America.
  • Pereyra F; Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, United States of America; Infectious Disease Division, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
  • Trowsdale J; Department of Pathology, Cambridge University, Cambridge, United Kingdom.
  • Lichterfeld M; Infectious Disease Division, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
  • Telenti A; Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Walker BD; Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, United States of America; Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America.
  • Allen RL; St George's Medical School, University of London, London, United Kingdom.
  • Carrington M; Cancer and Inflammation Program, Laboratory of Experimental Immunology, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America; Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, United States of America.
  • Yu XG; Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, United States of America.
PLoS Genet ; 10(3): e1004196, 2014 Mar.
Article em En | MEDLINE | ID: mdl-24603468
ABSTRACT
Natural progression of HIV-1 infection depends on genetic variation in the human major histocompatibility complex (MHC) class I locus, and the CD8+ T cell response is thought to be a primary mechanism of this effect. However, polymorphism within the MHC may also alter innate immune activity against human immunodeficiency virus type 1 (HIV-1) by changing interactions of human leukocyte antigen (HLA) class I molecules with leukocyte immunoglobulin-like receptors (LILR), a group of immunoregulatory receptors mainly expressed on myelomonocytic cells including dendritic cells (DCs). We used previously characterized HLA allotype-specific binding capacities of LILRB1 and LILRB2 as well as data from a large cohort of HIV-1-infected individuals (N = 5126) to test whether LILR-HLA class I interactions influence viral load in HIV-1 infection. Our analyses in persons of European descent, the largest ethnic group examined, show that the effect of HLA-B alleles on HIV-1 control correlates with the binding strength between corresponding HLA-B allotypes and LILRB2 (p = 10(-2)). Moreover, overall binding strength of LILRB2 to classical HLA class I allotypes, defined by the HLA-A/B/C genotypes in each patient, positively associates with viral replication in the absence of therapy in patients of both European (p = 10(-11)-10(-9)) and African (p = 10(-5)-10(-3)) descent. This effect appears to be driven by variations in LILRB2 binding affinities to HLA-B and is independent of individual class I allelic effects that are not related to the LILRB2 function. Correspondingly, in vitro experiments suggest that strong LILRB2-HLA binding negatively affects antigen-presenting properties of DCs. Thus, we propose an impact of LILRB2 on HIV-1 disease outcomes through altered regulation of DCs by LILRB2-HLA engagement.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glicoproteínas de Membrana / Receptores Imunológicos / Antígenos de Histocompatibilidade Classe I / Infecções por HIV / Imunidade Inata Limite: Female / Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glicoproteínas de Membrana / Receptores Imunológicos / Antígenos de Histocompatibilidade Classe I / Infecções por HIV / Imunidade Inata Limite: Female / Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article